Triterpenoids as new promising anticancer drugs.

abstract：:An i.v. formulation of rubitecan (9-nitrocamptothecin) was evaluated in five human solid tumor xenograft models. Rubitecan in IDD-P, a particulate suspension of the insoluble analog, produced significant tumor growth delay in athymic nude mice bearing A375 melanoma, and MX-1 breast, SKMES non-small-cell lung, Panc-1 p...

journal_title：Anti-cancer drugs

authors： Sands H,Mishra A,Stoeckler JD,Hollister B,Chen SF

更新日期：2002-10-01 00:00:00

abstract：:In a retrospective study, we calculated the treatment and follow-up costs of patients with newly diagnosed multiple myeloma. The total treatment programme consisted of eight phases: VAD or VAMP chemotherapy, follow-up I, high-dose melphalan followed by transplantation of whole blood, follow-up II, collection of periph...

journal_title：Anti-cancer drugs

authors： Buijt I,Ossenkoppele GJ,Uyl-de Groot CA,Huijgens PC

更新日期：1998-11-01 00:00:00

abstract：:Lipoplatin, currently under phase III evaluation, is a novel liposomal cisplatin formulation highly effective against cancers. Lipoplatin has eliminated or reduced the systemic toxicity frequently seen for cisplatin. The objective of the present study was to determine whether the cytotoxic effect of lipoplatin is depe...

journal_title：Anti-cancer drugs

authors： Fedier A,Poyet C,Perucchini D,Boulikas T,Fink D

更新日期：2006-03-01 00:00:00

abstract：:The efficacy of trastuzumab beyond metastatic disease progression (PD) is controversial. We retrospectively analyzed 213 patients with HER2-positive metastatic breast cancer treated with trastuzumab-based therapies between November 1998 and December 2010. Out of 213 patients, 134 (58%) had received trastuzumab consecu...

journal_title：Anti-cancer drugs

authors： Esposito A,Munzone E,Bagnardi V,Adamoli L,Sciandivasci A,Cullurà D,Goldhirsch A,Nolè F

更新日期：2012-11-01 00:00:00

abstract：:The sea, covering 70% of the Earth's surface, offers a considerably broader spectrum of biological diversity than terra firma. Containing approximately 75% of all living organisms, the marine environment offers a rich source of natural products with potential therapeutic application. Marine organisms have evolved the ...

journal_title：Anti-cancer drugs

authors： Jimeno JM

更新日期：2002-05-01 00:00:00

abstract：:Oxaliplatin (L-OHP), irinotecan (CPT-11) and 5-fluorouracil (5-FU) have shown their efficacy in metastatic colorectal cancer. The synergism of these drugs has been demonstrated in vivo and in vitro. The aim of this study was to determine the recommended dose of the triple combination of L-OHP, CPT-11 and CI 5-FU for a...

journal_title：Anti-cancer drugs

authors： Abad A,Massutí B,Gallego J,Yuste AL,Manzano JL,Carrato A,Antón A,Marfa X,Diaz-Rubio E,Spanish Cooperative Group for Gastrointestinal Tumor Therapy.

更新日期：2004-06-01 00:00:00

abstract：:We performed a phase II, Southwest Oncology Group (SWOG) clinical trial of recombinant human interleukin-4 (rhuIL-4) in patients with previously treated non-Hodgkin's lymphoma (NHL). We studied 18 eligible patients with low-grade and 21 patients with intermediate- or high-grade NHL. All patients had received prior che...

journal_title：Anti-cancer drugs

authors： Taylor CW,LeBlanc M,Fisher RI,Moore DF Sr,Roach RW,Elias L,Miller TP

更新日期：2000-10-01 00:00:00

abstract：:Gossypol [(2,2'-binaphthalene)-8,8'-dicarboxaldehyde-1,1',6,6',7,7'-hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl] 1a is a naturally occurring compound extracted from the cotton plant and has been extensively studied as an oral male contraceptive. Its favorable toxicity profile, and the more recent demonstration of anti-...

journal_title：Anti-cancer drugs

authors： Shelley MD,Hartley L,Groundwater PW,Fish RG

更新日期：2000-03-01 00:00:00

abstract：:Our objective was to clarify the efficacy of UFT administration after the complete resection of non-small cell lung cancer (NSCLC) at a single-center institution, avoiding the biases produced by interinstitutional differences. A total of 30 patients who underwent the complete resection of NSCLC at our hospital between...

journal_title：Anti-cancer drugs

authors： Ueda H,Sakada T,Kuwahara M,Motohiro A

更新日期：2004-01-01 00:00:00

abstract：:Cyclosporin A (CsA) is a calcium antagonist and can enhance the efficacy of some protein drugs, but its mechanism remains unknown. In this study, MAP30, a ribosome-inactivating protein reported to have apoptotic effects on cancer cells, was fused with S3, an epidermal growth factor receptor (EGFR)-targeting peptide. I...

journal_title：Anti-cancer drugs

authors： Song ZT,Zhang LW,Fan LQ,Kong JW,Mao JH,Zhao J,Wang FJ

更新日期：2018-09-01 00:00:00

abstract：:Chemically modified tetracycline 3 (CMT-3) is a potential anticancer drug because of its retained matrix metalloproteinases inhibitory property. In the present study,we showed that CMT-3 significantly inhibited the growth and proliferation of human hepatocellular carcinoma HepG2 cells. Novel mechanisms including incre...

journal_title：Anti-cancer drugs

authors： Zhao L,Xu J,Jiao Y,Wang H,Fan S

更新日期：2014-11-01 00:00:00

abstract：:Antimicrobial peptides of the cathelicidin family play a central role in the host defense system. Our group has reported previously that cathelicidin-related or cathelicidin-modified antimicrobial peptides, such as FF/CAP-18, have antiproliferative effects on the squamous cell carcinoma cell line SAS-H1 and colon canc...

journal_title：Anti-cancer drugs

authors： Kuroda K,Fukuda T,Okumura K,Yoneyama H,Isogai H,Savage PB,Isogai E

更新日期：2013-09-01 00:00:00

abstract：:Human colon cancer SW480 cells express the c-myc gene. On the other hand, SW480DDP cell lines resistant to cisplatin exhibited decreased c-myc gene expression, but their cell growth rates remained similar to those of their parental cells. Antisense oligonucleotides to c-myc inhibited c-myc expression and induced incre...

journal_title：Anti-cancer drugs

authors： Funato T,Kozawa K,Kaku M,Sasaki T

更新日期：2001-11-01 00:00:00

abstract：:We have examined the biological activity of keto-C-glycosides (KCGs), a new family of drugs displaying antiproliferative and cytotoxic properties on tumor cells. KCG1, the most powerful drug tested on epithelial derived neoplastic cells, was 25-125 times more cytostatic on epithelial cells than on lymphoma. By contras...

journal_title：Anti-cancer drugs

authors： Bennani-Baïti MI,Lafarge-Frayssinet C,Herscovici J,Monserret R,Antonakis K,Frayssinet C,Uriel J

更新日期：1992-08-01 00:00:00

abstract：:Individual response of disseminated cancer to chemotherapy is unpredictable. In vitro chemotherapy-induced apoptosis can be measured and might be a method to evaluate in vivo activity of tested drugs. In this report, tumor cells of a patient with signet cell carcinoma of the stomach and diffuse bone marrow infiltratio...

journal_title：Anti-cancer drugs

authors： Trojan J,Kim SZ,Engels K,Kriener S,Mitrou PS,Chow KU

更新日期：2005-01-01 00:00:00

abstract：:Thrombin is a potent mitogen for many tumor cells, suggesting that this enzyme may be involved in tumor genesis and metastasis. Inhibition of thrombin expressed on the surface of tumor cells may improve outcomes in some tumor cases. For this reason, a thrombin inhibitor to be applied in antitumor therapy must have fav...

journal_title：Anti-cancer drugs

authors： López ML,Nowak G

更新日期：2004-02-01 00:00:00

abstract：:Vinblastine at doses ranging from 0.2 to 6 mg/kg body weight was administered i.p. to mice in the absence or presence of the drugs PSC 833, cyclosporin A, mefloquine, quinidine and dipyridamole, all compounds that modulate the multidrug resistance pump and thus increase the accumulation of this cytotoxin in drug-resis...

journal_title：Anti-cancer drugs

authors： Lyubimov E,Lan LB,Pashinsky I,Stein WD

更新日期：1996-01-01 00:00:00

abstract：:Caffeic acid phenethyl ester (CAPE) is a major propolis component that possesses a variety of pharmacological properties such as antioxidant and anticancer effects. Herein, we investigated the effectiveness of CAPE on cytotoxicity of clinically used anticancer drugs, doxorubicin (DXR) and cisplatin (CDDP), in parental...

journal_title：Anti-cancer drugs

authors： Matsunaga T,Tsuchimura S,Azuma N,Endo S,Ichihara K,Ikari A

更新日期：2019-03-01 00:00:00

abstract：:This study aims to explore the effect and mechanism of pyruvate kinase M2 (PKM2) on chemotherapy resistance of estrogen receptor-positive breast cancer (ER BC) by regulating aerobic glycolysis. The expression of PKM2 in ER BC MCF-7 cells, T47D cells and MCF-7/ADR cells (which are subject to adriamycin/ADR induction) w...

journal_title：Anti-cancer drugs

authors： Qian Y,Bi L,Yang Y,Wang D

更新日期：2018-08-01 00:00:00

abstract：:Topoisomerase IIalpha (Topo IIalpha) is an essential nuclear enzyme with a role in the maintenance of DNA topology. Topo IIalpha is a target for several anticancer drugs and the levels of activity of this enzyme have been implicated in the development of drug resistance. Our objective was to identify regulatory transc...

journal_title：Anti-cancer drugs

authors： Allen KA,Williams AO,Isaacs RJ,Stowell KM

更新日期：2004-04-01 00:00:00

abstract：:Liver X receptor (LXR) has been exploited widely as a drug target in breast cancer treatment, and various mechanisms underlying the effects of LXR in this area are well studied. The activated LXR plays important roles in estrogen receptor α (ERα) breast cancer cells, such as reducing cell proliferation and arresting c...

journal_title：Anti-cancer drugs

authors： Wu Y,Yu DD,Yan DL,Hu Y,Chen D,Liu Y,Zhang HD,Yu SR,Cao HX,Feng JF

更新日期：2016-06-01 00:00:00

abstract：:Temozolomide (TMZ) combination with whole-brain radiotherapy (WBRT) has been tested by many randomized controlled trials in the treatment of brain metastases (BMs) in China and other countries. We performed an up-to-date meta-analysis to determine (i) the log odds ratios (LORs) of objective response (ORR) and adverse ...

journal_title：Anti-cancer drugs

authors： Bai GR,An JB,Chu Y,Wang XY,Li SM,Yan KJ,Lü FR,Gu N,Griffin AN,Sun BY,Li W,Wang GC,Zhou SP,Sun H,Liu CX

更新日期：2016-01-01 00:00:00

abstract：:Mitomycin C (MMC) in combination with infusional 5-fluorouracil (5-FU) is a well-tolerated active combination therapy for advanced gastric cancer. Pegylated liposomal doxorubicin (Caelyx) has been combined with this regimen in a phase I study exhibiting promising activity in patients with upper gastrointestinal tumors...

journal_title：Anti-cancer drugs

authors： Gnad-Vogt SU,Hofheinz RD,Saussele S,Kreil S,Willer A,Willeke F,Pilz L,Hehlmann R,Hochhaus A

更新日期：2005-04-01 00:00:00

abstract：:Since the early 1990s, mitoxantrone has been used as a chemotherapeutic agent for adjuvant intravesical treatment following transurethral resection of superficial transitional cell carcinomas of the bladder. Although its efficacy as adjuvant intravesical therapy remains questionable and its use has not gained wide acc...

journal_title：Anti-cancer drugs

authors： Giannakopoulos S,Pantazis T,Kalaitzis C,Antoniou D,Patris E,Touloupidis S

更新日期：2008-03-01 00:00:00

abstract：:Telomerase is an enzyme responsible for telomere maintenance in almost all human cancer cells, but generally not expressed in somatic ones. Therefore, antitelomerase therapy is a potentially revolutionary therapeutic strategy, and the antitumor activity of telomerase inhibitors (TI) has been studied extensively recent...

journal_title：Anti-cancer drugs

authors： Morais KS,Guimarãesb AFR,Ramos DAR,Silva FP,de Oliveira DM

更新日期：2017-08-01 00:00:00

abstract：:To devise a meaningful nutritional therapy in cancer, a greater understanding of nutritional dimensions as well as of expectations of patients and disease impact is essential. We have shown that nutritional deterioration in patients with gastrointestinal and head and neck cancer was multifactorial and mainly determine...

journal_title：Anti-cancer drugs

authors： Ravasco P

更新日期：2011-08-01 00:00:00

abstract：:The present study was carried out to explore the effect of sinensetin in human T-cell lymphoma Jurkat cells and to reveal the underlying molecular mechanisms. We found that sinensetin significantly impeded Jurkat cell proliferation in a dose-dependent and time-dependent manner. Additionally, sinensetin treatment trigg...

journal_title：Anti-cancer drugs

authors： Tan KT,Lin MX,Lin SC,Tung YT,Lin SH,Lin CC

更新日期：2019-06-01 00:00:00

abstract：:Electrochemotherapy using intratumoral cisplatin administration was tested on EAT tumors in mice. Mice were treated with eight electric pulses (100 micros, 1 Hz, 1040 V) and/or cisplatin (1, 2, 4 and 8 mg/kg). Cisplatin treatment resulted in up to 20 days of tumor growth delay. Electrochemotherapy resulted in tumor cu...

journal_title：Anti-cancer drugs

authors： Cemazar M,Milacic R,Miklavcic D,Dolzan V,Sersa G

更新日期：1998-07-01 00:00:00

abstract：:Cancer invasion and metastasis are highly complex processes and a serine protease urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system has been postulated to play a central role in the mediation of cancer progression. Of note, malignant tumor urokinase-type plasminogen activator an...

journal_title：Anti-cancer drugs

authors： Nozaki S,Endo Y,Nakahara H,Yoshizawa K,Ohara T,Yamamoto E

更新日期：2006-11-01 00:00:00

abstract：:Colorectal cancer occurs throughout the world but is most common in developed countries. Cancer progression is believed to be driven by genetic mutations in this complex condition. Risk factors for developing colorectal cancer include a genetic family history, long-term ulcerative colitis, and colonic polyps. The use ...

journal_title：Anti-cancer drugs

authors： Ma W,Liu X,Du W

更新日期：2019-02-01 00:00:00